The ability of cancer cells to predominantly produce energy by a high rate of glycolysis followed by lactic acid fermentation in the cytosol, rather than by glycolysis followed by oxidation of pyruvate in the mitochondria, as most normal cells do.
. A complex dynamic interplay exists between the expanding neoplastic mass and the tumour environment, which is affected by the metabolic requirements of cancer cells and by their products, such as secreted proteins (for example, extracellular matrix components and proteases) and metabolites.
Upregulated glucose metabolism is a hallmark of invasive cancers 3 . In normal cells glucose is converted to glucose-6-phosphate and subsequently to pyruvate, which is then oxidized in the mitochondria to carbon dioxide and water; this releases 38 moles of ATP per mole of glucose 3 . However, inadequate oxygen delivery to some regions of tumours leads to hypoxia, which restricts oxidative phosphorylation. As a consequence, hypoxic tumour cells shift their metabolism towards glycolysis so that the pyruvate generated in the first step of the process is reduced to lactate, generating only 2 moles of ATP per mole of glucose. This is a less energy-efficient process but it does not depend on oxygen. Furthermore, glycolysis often persists even after reoxygenation because the obtained metabolic intermediates (that is, lactate and pyruvate) can be used for the biosynthesis of amino acids, nucleotides and lipids, thus providing a selective advantage to proliferating tumour cells. This explains Warburg's observation of high glucose consumption and high lactate production in tumour tissues [3] [4] [5] (known as the Warburg effect).
Oncogenic metabolism also generates an excess of protons and carbon dioxide, which are kept in equilibrium with carbonic acid by the enzyme carbonic anhydrase [3] [4] [5] [6] [7] [8] [9] . Thus, increased glucose metabolism in tumour cells leads to enhanced acidification of the extracellular milieu, which is frequently accompanied by various levels of hypoxia. This phenotype confers a substantial Darwinian growth advantage to tumour cells over normal cells, which undergo apoptosis in response to such an acidic extracellular environment 3 . Tumour cells have evolved various mechanisms to cope with the acidic and hypoxic stress mentioned above. They eliminate acidic catabolites by ion transporters and pumps to preserve a slightly alkaline intracellular pH (pH i ), which is optimal for cell proliferation and tumour survival [3] [4] [5] [6] [7] [8] [9] [10] . Acid export leads to a reduction in the extracellular pH (pH e ) to values as low as 6.0 (the usual pH e in tumours is in the range of 6.5-7.0) 3 , which is a salient feature of the tumour microenvironment [3] [4] [5] [6] [7] [8] [9] . As well as triggering the overexpression of many proteins involved in glucose metabolism -such as the glucose transporter GLUT1 (also known as SLC2A1) and pH-regulating proteins such as carbonic anhydrase 9 (CA9) 3, 4, 10 -hypoxia also constitutes a detrimental feature for radiotherapy, as oxygen is needed to oxidize the radiation-induced DNA free radicals that subsequently lead to tumour cell death 4 . pH homeostasis in any cell type is a complicated process that involves many proteins and buffer systems 4 . In tumour cells, these processes are even more complex owing to the internal compartment being slightly more alkaline (pH 7.4 or more) and the external compartment being more acidic than in normal cells [4] [5] [6] [7] [8] [9] . A variation in the pH i /pH e ratio as low as 0.1 pH units may disrupt important biochemical and/or biological processes such as ATP synthesis, enzyme function and the proliferation, migration, invasion and metastasis of tumour cells 5 ; consequently, a tight regulation of these processes has evolved [5] [6] [7] [8] [9] . Changes in the pH i as low as 0.1-0.2 pH units also trigger mechanisms of alternative splicing of extracellular matrix components that generate different isoforms of tenascin and fibronectin, which are typical of tumour cells and not normal cells 11, 12 . These alternatively spliced proteins are not involved in pH regulation but they may constitute a novel antitumour mechanism
.
Several sophisticated molecular mechanisms are responsible for maintaining the alkaline pH i and the acidic pH e in tumour cells [5] [6] [7] [8] [9] [10] . These include proteins that import weak bases (such as the HCO 3 -ion) into the cells and proteins that export the weak acids generated during metabolism -such as carbon dioxide, carbonic acid or lactic acid -out of the cells 4 . In addition, H + ions are directly extruded from the cells, either in exchange for other cations (such as Na + ) or by means of the vacuolar ATPase (V-ATPase) [5] [6] [7] [8] [9] 13, 14 .
The main players involved in the regulation of tumour pH are shown in FIG. 1 and include: CA2, CA9 and CA12 (REFS 15-17); V-ATPase 18 ; the anion exchangers AE1 (also known as SLC4A1), AE2 (also known as SLC4A2) and AE3 (also known as SLC4A3) 19, 20 ; Na + /HCO 3 -co-transporters (NBCs) 14 ; electroneutral Na
-exchanger (NDCBE; also known as SLC4A8) 14 ; Na + /H + exchanger 1 (NHE1; also known as SLC9A1) 14 ; and the monocarboxylate transporters MCT1, MCT2, MCT3 and MCT4 (REFS 21, 22) . Many of these proteins exist as multiple isoforms, which represents a complication from the medicinal chemistry viewpoint, as a good drug should target only the desired isoform. Carbonic anhydrases 15, 16 , anion exchangers and MCTs all have several isoforms and not all of these are associated with tumours [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . There are various approaches for targeting one or more of these proteins to restore both pH i and pH e in cancer cells towards normal values and halt tumour growth. This constitutes an antitumour mechanism that has not yet been exploited by any of the classical anticancer drugs. Proof-of-concept studies that were performed during the past few years have led to the validation of some of these proteins as new anticancer drug targets. This Review discusses recent advances in the development of pharmaceutical agents that interfere with pH regulation in tumours, with a special focus on carbonic anhydrases.
Tumour-associated carbonic anhydrases α-carbonic anhydrases (EC 4.2.1.1) are metalloenzymes that are widespread in higher vertebrates, including humans 15, 16 . So far, 16 isoforms of carbonic anhydrase have been characterized in mammals (15 in humans; CA15 is not expressed in primates), which differ in their subcellular localization, catalytic activity and susceptibility to different classes of inhibitors. There are cytosolic isozymes (CA1, CA2, CA3, CA7 and CA13), membrane-bound isozymes (CA4, CA9, CA12, CA14 and CA15), mitochondrial isozymes (CA5A and CA5B) and secreted isozymes (CA6). Three acatalytic isoforms -CA8, CA10 and CA11 -called carbonic anhydrase-related proteins have also been identified 24, 25 . Most carbonic anhydrases are very efficient catalysts for the reversible hydration of carbon dioxide to bicarbonate and protons (CO 2 + H 2 O ↔ HCO 3 -+ H + ), which is a vital reaction in most organisms 15, 16 . The HCO 3 --carbonic acid system is the main buffer of pH in all living cells 15, 16 . Carbon dioxide is generated in high amounts as the final product of oxidative phosphorylation, and is immediately converted to HCO 3 -by carbonic anhydrases. The uncatalysed hydration reaction of this gas is too slow to meet the physiological needs of the cell, which is why so many carbonic anhydrase isoforms have evolved 15, 16 . In mammals carbonic anhydrases are involved in processes such as respiration and acid-base regulation, electrolyte secretion, bone resorption and calcification, and in biosynthetic reactions that require HCO 3 -as a substrate (such as lipogenesis, gluconeogenesis and ureagenesis), whereas in plants and bacteria these enzymes are also involved in photosynthesis and carbon dioxide-fixation mechanisms 15, 16, 26 . Two carbonic anhydrase isozymes (CA9 and CA12) are overexpressed in many tumours, and are associated with cancer progression and response to therapy [15] [16] [17] 27, 28 . CA9 is expressed in the stomach and peritoneal lining, but it is ectopically induced and overexpressed in several types of solid tumours, predominantly owing to strong transcriptional activation of hypoxia-inducible transcription factor 1 (HIF1) 12, [15] [16] [17] 28, 29 . Interestingly, CA9 is the most strongly overexpressed gene in response to hypoxia in human cancer cells 28, 30 , and it is also the most active isoform of carbonic anhydrase for the car bon dioxide hydration reaction 29, 31 . The X-ray crystal structure of CA9 reveals that it is a dimeric enzyme 32 , unlike all other carbonic anhydrase isoforms known so far, which are monomeric. Like CA9, CA12 is a transmembrane isoform with an extracellular active site 27 but it has lower catalytic activity than CA9 (REFS 15, 33) . CA12 is also expressed in many tumours but it is more diffuse in some healthy tissues 27 . Given that carbonic anhydrases are considerably simple enzymes that are biochemically well characterized and have a multitude of known inhibitors 15, 16 (FIG. 2) , their potential as anticancer drug targets is very attractive.
Sulphonamides as carbonic anhydrase inhibitors.
Primary sulphonamides, sulphamates and sulphamides act as carbonic anhydrase inhibitors (CAIs) by binding to the catalytic Zn 2+ ion in the active site of the enzyme and blocking its function 15, 16 . Some of these compounds inhibit both CA9 and CA12 (REFS 15, 16, (33) (34) (35) (36) (37) . Many such compounds were specifically designed for targeting these tumour-associated isoforms of carbonic anhydrase 38 . The main approaches for developing such compounds are listed below.
One approach is the addition of fluorescent tags to generate fluorescent sulphonamides (compound 1; FIG. 2) , which are used for imaging purposes and for determining the role of CA9 in tumour acidification 28, 39 . Another approach is the addition of a positive or negative charge to sulphonamide and sulphamate CAIs (compound 2; FIG. 2 ) so that they are unable to cross plasma membranes and thus selectively inhibit extracellular carbonic anhydrases, which include CA9 and CA12 (REF. 40 ). Such compounds are completely different from the classical sulphonamide inhibitor acetazolamide, (compound 3; FIG. 2) which is a promiscuous, potent inhibitor of most carbonic anhydrase isoforms. Acetazolamide has been an important lead for generating other inhibitors with a better selectivity profile (compounds 4 and 5; FIG. 2) 41 , and has led to the development of compounds that are activated by hypoxia and exploit the reducing conditions of hypoxic tumours to convert an inactive prodrug Box 1 | Tumour-associated splice isoforms regulated by intracellular pH Elevation of the intracellular pH (pH i ) in tumour cells leads to the generation of alternatively spliced extracellular matrix components, which may serve as targets for antibody-based cancer therapy 11, 12 . The insertion or omission of extra domains in tenascin C illustrates this process.
Tenascins are a family of four extracellular matrix glycoproteins that are found in vertebrates. They are typically present in many different connective tissues. Tenascins contribute to matrix structure and influence the behaviour of cells that are in contact with the extracellular matrix. Several isoforms of tenascin C can be generated as a result of different patterns of alternative splicing in the region between domains A1 and D (see figure) . In normal tissues and at pH i values of around 7.0, cells typically produce the 'small' tenascin C splice isoform, which does not include domains A1 to D. When cells are artificially exposed to basic pH values -for example, in cell culture experiments, fetal tissues (which typically have basic pH values of around 7.4-7.5 units) or in aggressive forms of cancer -changes of 0.2-0.3 pH units in the pH i value lead to a complete switch towards the formation of the 'large' tenascin C splice isoform, which includes domains A1 to D 11, 12 . Interestingly, tenascin C splice isoforms are commonly found in the tumour stroma and/or around tumour blood vessels [92] [93] [94] [95] [96] [97] [98] and serve as markers of angiogenesis 99 . The regulation of alternative splicing of tenascin C is complicated by the observation that the extra domain C displays a more restricted pattern of expression than the other domains between A1 and D 100, 101 . However, whenever this domain is inserted into the tenascin C molecule (for example, in high-grade astrocytomas), it tends to accumulate around neovascular tumour structures [100] [101] [102] . The A1 domain of tenascin C is the target of the F16 antibody, whereas the 81C6 antibody recognizes domain D.
Similarly to tenascin C, other components of the extracellular matrix undergo alternative splicing, and the corresponding extra domains represent some of the best characterized markers of tumour angiogenesis and the tumour stroma. The alternatively spliced domains extra domain A (EDA) and extra domain B (EDB) of fibronectin, which are targeted by the F8 and L19 antibodies, respectively, exhibit a high level of conservation among species and are virtually undetectable in normal tissues; however, they are abundantly expressed in the stroma and neovasculature of most aggressive types of human cancers 96, [102] [103] [104] [105] [106] [107] [108] [109] [110] . Similarly, systematic chemical proteomics studies 107, [111] [112] [113] have recently shown that another component of the extracellular matrix, periostin, exists in several splice isoforms that are abundantly found in most types of cancers [111] [112] [113] [114] . . The addition of sugar moieties to CAIs -leading to the formation of sugar-containing sulphonamides, sulphamates and sulphamides that are highly hydrophilic and unable to cross membranes easily -is another approach; these sugar-containing sulphonamides possess an enhanced selectivity for extracellular carbonic anhydrases such as CA9 and CA12 (compounds 7 and 8; FIG. 2) 15, 16, 40 . Other approaches for targeting these enzymes involve investigating different chemotypes of sulphonamides 42, 43 or using nanoparticles to design CAIs 44 . The first study linking the inhibition of CA9 with tumour shrinkage used the fluorescent sulphonamide (compound 1, n=1) and the cationic compound 2 (REF 28) . This study showed that these derivatives -which have a high affinity for CA9 and CA12 (inhibition constants of 5-24 nM) 36 -are useful probes for hypoxic tumours 28, 45, 46 . Compound 1 (n=1) inhibits CA9 only under hypoxic conditions in vivo, in cell cultures or in animals with transplanted tumours. Although the biochemical rationale for this phenomenon is not yet understood, these properties may be exploited in the design of diagnostic tools for imaging hypoxic tumours.
Compound Generic
It is interesting to note that in tumour cell cultures that were treated with compound 1 (n=1 or n=2) or compound 2, the acidic pH e was reversed towards more normal pH values, which was undoubtedly due to the inhibition of the tumour-associated carbonic anhydrases 28, 45, 46 . Compound 1 (n=1), with a high affinity for CA9, was shown via non-invasive fluorescent imaging, to bind to cells only when the CA9 protein was expressed and when cells were hypoxic, in an in vivo model of cancer 46 . Fluorescently labelled sulphonamides may therefore provide a powerful tool for visualizing hypoxia responses in solid tumours and could be used to select patients for CA9-directed therapies 46 . An interesting study reported that in hypoxic LS174Tr tumour cells that overexpress both CA9 and CA12, it was possible to genetically silence one or both carbonic anhydrase isoforms 47 . Genetic silencing of CA9 alone caused a 40% reduction in xenograft tumour volume and led to the overexpression of CA12. However, these cells were kept at an artificially low HCO 3 -concentration, and this observation has not been reproduced 45, 48 . Genetic silencing of both CA9 and CA12 led to an 85% reduction in tumour growth, which suggests that CA9 and CA12 are major tumour prosurvival pH-regulating enzymes 47 . Membrane-impermeable sulphonamide derivatives (compounds 4 and 5), which are based on the acetazolamide scaffold to which either fluorescein-carboxylic acid or albumin-binding moieties were attached, suppressed tumour growth in mice with xenografts of a clear-cell renal cell carcinoma cell line when they were administered alone or in combination with other anticancer drugs 41 . These data were the first to demonstrate in vivo the potential of sulphonamides (or related agents acting on CA9 or CA12) as alternative anticancer drugs 15, 16, 41 . Since then, potent bis-sulphonamide CA9 inhibitors that accumulate in colorectal adenocarcinoma xenografted tumour sections in mice have also been identified in a library of one million DNA-encoded chemical compounds 41 . Interestingly, in a mouse model of breast cancer the overexpression of CA9 in hypoxic conditions led to the formation of spontaneous lung metastasis 48 . Treatment of the mice harbouring such orthotopic tumours with compound 1 (n=2), at a dose of 75 mg per kg, led to the regression of orthotopic mammary tumours and inhibited the formation of lung metastases 48 . However, even stronger effects were observed with the ureidosulphonamide inhibitor (compound 9; FIG. 2) , a CA9 inhibitor with low nanomolar potency, which substantially inhibited both the growth of primary tumours and metastases in the same animal model, at doses of 30-45 mg per kg 47, 50 . Thus, sulphonamide CAIs that target CA9 seem to be effective at inhibiting the growth of both the primary tumour and metastases, at least in this animal model 47, 49 . Some of these compounds are in advanced preclinical evaluation 47, 50 (TABLE 1) . It has also been observed that combining CA9 inhibition (via sulphonamide or sulphamate compounds) with tumour irradiation has a synergistic antitumour effect in HT29 carcinoma cells xenografted in mice 51 . + exchangers (NHEs); the plasma membrane proton pump vacuolar ATPase (V-ATPase); anion exchangers (AEs); Na + /HCO 3 -co-transporters (NBCs); and carbonic anhydrases (CA2, CA9 and/or CA12). The glucose transporter GLUT1 (which is upregulated in most tumours) transports glucose into tumour cells. The intracellular tumour pH (pH i ) is slightly alkaline (pH 7.2-7.4), whereas the extracellular pH (pH e ) is slightly acidic (pH 6.5-7.0). BT, HCO 3 -transporter; CBP, cyclic AMP-responsive element-binding (CREB) protein; HIF1, hypoxia-inducible transcription factor 1; p300, histone acetyltransferase p300. Alternative CAIs. Coumarins and thiocoumarins were only recently discovered to have carbonic anhydraseinhibiting properties, and their mechanism of inhibition has subsequently been deciphered 42, 43 . The nat ural product 6-(1S-hydroxy-3-methylbutyl)-7-methoxy-2H-chromen-2-one (compound 10; FIG. 2) is hydrolysed within the carbonic anhydrase active site, leading to the formation of the 2-hydroxycinnamic acids (compound 11; FIG. 2) , which represent the de facto enzyme inhibitor. This new class of CAIs binds to carbonic anhydrase in its hydrolysed form at the entrance of the active site, and does not interact with the metal ion, thus constituting a class of CAIs with a new mechanism of action 42, 43 . As well as the natural coumarin compound (compound 10), compounds 12 and 13 (GC-205) (FIG. 2) that were discovered thereafter have been shown to be potent and selective inhibitors against some human isoforms of carbonic anhydrase. Compounds such as 12 and GC-205 are selective CA9 and CA12 inhibitors with a low nanomolar potency that do not substantially inhibit the off-target isoforms CA1 and CA2 (REFS 51,52). Furthermore, like the sulphonamide CAIs, GC-205 was recently shown to inhibit the growth of primary tumours and metastases in an animal model of breast cancer 47 and is in advanced preclinical evaluation as an anti cancer and antimetastasis agent 47 (TABLE 1) .
It has been demonstrated that the protein tyrosine kinase (PTK) inhibitors that are in clinical use 53 -imatinib (Gleevec; Novartis (compound 14; FIG. 2) ) and nilotinib (Tasigna; Novartis (compound 15; FIG. 2) ) -also inhibit some physiologically relevant carbonic anhydrase isoforms, albeit less efficiently than sulphonamides and coumarins 54 . Indeed, imatinib and nilotinib can inhibit CA1, CA2, CA9 and CA12 at nanomolar concentrations; however, their mechanism of inhibition is not yet understood as X-ray crystal structures for the adducts of any carbonic anhydrase isozymes with these compounds have not been obtained so far 54 . Nonetheless, this is an important finding that may explain their potent antitumour effects in malignancies such as gastrointestinal stromal tumours, which overexpress CA2 (REF. 55 ). A synergy between PTK inhibition and the inhibition of cancer-associated carbonic anhydrase isoforms could explain the potent therapeutic effect observed with imatinib and nilotinib in various types of metastatic cancer. Studies in experimental models of cancer combining a selective PTK inhibitor and a selective CAI would be required to investigate this hypothesis.
Monoclonal antibodies may represent the most convenient avenue for the selective inhibition of CA9 and CA12 (REFS 56, 57) . Compared to rodent antibodies, chimeric and humanized antibodies are less immunogenic in humans 58 , can be generated easily and with excellent specificity 59 , and do not spontaneously cross the cell membrane 60 . M75 is a monoclonal antibody with a high specificity for CA9 that targets the proteoglycan domain of the enzyme 61 . It has been used in immunohistochemical and western blot studies for identifying CA9 in various types of tumours, and a radiolabelled form of this antibody is used for imaging tumours via positron emission tomography (PET). The biological distribution of this radiolabelled monoclonal antibody in nude mice with HT-29 human colorectal carcinoma xenografts that overexpressed CA9 in hypoxic conditions demonstrated that the radioactivity accumulated only in the tumour 61 . Thus, monoclonal antibodies labelled with various PET tracers may be used successfully for imaging hypoxic tumours that overexpress CA9.
WX-G250 is another CA9-specific chimeric monoclonal antibody that is in Phase III clinical trials as an adjuvant therapy for the treatment of non-metastasized renal cell carcinoma in patients who are at a high risk of recurrence after resection of the primary tumour 62 . Phase III trials are also underway at Wilex for the treatment of metastatic renal cell carcinoma in combination with interleukin-2 or interferon-α 62 . Antibody binding to CA9 on tumour cells triggers antibody-dependent cellular cytotoxicity, an immune reaction in which effector cells such as natural killer cells are engaged in a binding interaction via their Fcγ receptors and are activated to release toxic granuli 60 . Recently, CA12-specific monoclonal antibodies have been generated and characterized.
Such monoclonal antibodies inhibit the enzymatic activity of CA12 in the low nanomolar or subnanomolar range and also inhibit tumour growth 56 . Somewhat surprisingly, considerable differences in tumour-targeting performance have been observed among different CA9-specific antibodies, with the approaches developed by the Boerman group resulting in some of the highest tumour uptake values ever reported in the field of antibody-based tumour targeting 63, 64 . The observation that pre-targeting strategies (that is, the sequential administration of a bi-specific antibody, which is specific to CA9 and a metal chelator, followed by the intravenous injection of the complex of the metal chelator with a suitable radionuclide) lead to an extremely high and rapid uptake of radioactivity in mouse models of renal cell carcinoma 64 suggests that small high-affinity ligands may be distributed more rapidly into tumour tissues than antibodies.
Bayer, MorphoSys and Seattle Genetics have advanced a CA9-specific antibody, coupled to the potent cytotoxic drug auristatin, to Phase I clinical trials in patients with various types of solid cancer (TABLE 1) . In the future, it may be possible to bypass antibodies with high-affinity CA9 ligands (for example, sulphonamide derivatives), which could serve as modular targeting agents for pharmacodelivery applications. These innovative biomedical strategies bear certain analogies to the successful use of folate derivatives for targeting tumours overexpressing folate receptors, as pioneered by the Low group 65 . Indeed, many studies have shown that antibodies are restricted in their ability to access the most hypoxic and poorly vascularized regions of tumours [63] [64] [65] . Such problems are not normally encountered with small molecules such as CA9 and CA12 inhibitors 15 .
V-ATPase inhibitors and proton pump inhibitors V-ATPase is an ATP-dependent proton pump that is involved in the acidification of intracellular compartments and the extrusion of protons through the cytoplasmic membrane of the cell 18, 66, 67 . This enzyme has a crucial role in regulating the pH of normal cells and tumour cells. It consists of multiple subunits (formed from several multisubunit proteins) with both cytosolic and transmembrane domains 18, 66, 67 . In addition to proton transfer processes, V-ATPase is involved in a host of physiological and pathological processes, such as endocytosis, intracellular trafficking and the acidification of endosomes, as well as the creation of an appropriate microenvironment for protein transport 18 . It is therefore not improbable that V-ATPase also participates in the regulation of pH e 66, 67 . There are various classes of V-ATPase inhibitors, such as the macrocyclic antibiotics bafilomycin A and concanamycin A, a large series of benzolactone enamides incorporating a salicylic acid scaffold, the macro cyclic antibiotic archazolid and some free radical indolyls 18 , but all of these inhibitors are highly toxic and difficult to use as tools for understanding the role of V-ATPase in tumorigenesis. However, one study has suggested that bafilomycin A retards the growth of pancreatic xenograft tumours 68 .
The similarity between V-ATPase and H + ,K + ATPase, the enzyme involved in proton secretion in the stomach, prompted the investigation of proton pump inhibitors (PPIs) of the omeprazole type for inhibiting V-ATPase 66, 69 . Such compounds -including omeprazole, pantoprazole, lansoprazole and rabeprazole (compounds 16, 17, 18 and 19; FIG. 3) , among others -are widely used clinically as antacids and are prodrugs that require acidity to be activated 66, 67, 69, 70 . In an acidic environment they undergo a transformation that leads to the formation of a sulphenamide, which reacts with cysteine residues of the proton pump and results in its inactivation 70 . PPIs may also target the acidic (hypoxic) tumour mass, where they are metabolized as in the stomach and block the formation and trafficking of protons 6, 66 . Proton pump inhibition was shown to trigger rapid cell death as a result of intracellular acidification, caspase activation and early accumulation of reactive oxygen species in tumour cells 66 . Many human tumours -including melanomas, osteosarcomas, lymphomas and various adenocarcinomas -were shown to be responsive to PPIs 6, 66 . Metastatic tumours seemed to be even more responsive to PPIs as they are generally more acidic than most primary tumours 66, 69 . Two clinical trials are testing the effectiveness of PPIs in patients with chemosensitizing melanoma and osteosarcoma 66 . Indeed, tumour acidity represents a very potent mechanism of chemoresistance 71 , as most cytotoxic agents are weak bases that are quickly protonated outside the cell and prevented from reaching specific cell ular targets. Compounds that show enhanced uptake by hypoxic tumours (with a pH e value in the range of 6.5-7.0) are those that possess a logarithmic acid dissociation constant (pKa) in the range of 5-6 -the carboxylic acids 71 . Further studies will determine whether PPIs represent a new class of antitumour agents with a low level of systemic toxicity compared with standard chemotherapeutic agents.
Interference with HCO 3 -transport HCO 3 -transporters facilitate the movement of the membrane-impermeant HCO 3 -ion across biological membranes 72 . They are phylogenetically clustered into three classes: electroneutral Cl -/HCO 3 -exchangers of the solute carrier 4A (SLC4A) family, the anion exchangers; the NBC family of Na + /HCO 3 -co-transporters; and anion transporters of the SLC26 family 19, 20, 72 .
Inhibiting the anion exchangers. The anion exchanger family is composed of three isoforms: AE1, AE2 and AE3. Human AE1 is formed from a 43 kDa aminoterminal domain, a 55 kDa membrane-spanning domain (which is responsible for Cl -/HCO 3 -exchange activity) and a 33 kDa cytoplasmic carboxy-terminal domain that contains the binding site for CA2 (REF. 72 ). AE2 is the most widely expressed isoform, whereas AE3 is predominantly expressed in excitable tissues and throughout the gastrointestinal tract 72 . The physical and functional interactions between these HCO 3 -transporters and the various carbonic anhydrase isoforms 72 suggest that they could form a complex. This has been demonstrated for the AE1-CA2 metabolon 73 . In this complex, carbonic anhydrases supply the HCO 3 -substrate for transport (by catalysing their physiological reaction: the hydration of CO 2 to HCO 3 -and H + ), whereas the HCO 3 -transporter translocates the membrane-impermeant HCO 3 -into or out of the cell 72, 73 ; however, carbonic anhydrases may also remove HCO 3 -by catalysing the reverse reaction.
CA9 has been demonstrated to form a metabolon with isoform AE2 (REF. 74 ). The concerted action of the enzyme and the anion exchanger may lead to the high pH i that is characteristic of tumour cells and to the acidification of the pH e , through the shuttling of HCO 3 -into or out of the cell. This mechanism may also explain why an intracellular isoform (CA2) and two extracellular isoforms (CA9 and CA12) are involved in pH regulation in cancer cells 15, 72 . 4,4′-Diisothiocyano-2,2′-stilbenedisulphonic acid (DIDS) (compound 20; FIG. 4) and structurally related stilbenes act as inhibitors of anion exchangers, but they also indiscriminately inhibit other HCO 3 -transporters 75 . These compounds initially block the anion exchangers reversibly and later block them irreversibly 75 . DIDS has antitumour activity and it induces apoptosis in HA22T hepatocellular carcinoma cells overexpressing AE2
Another potent CA9 and CA12 inhibitor, celecoxib (Celebrex; Pfizer (compound 21 ; FIG. 4) ) 15 , and several other potent sulphonamide CAIs such as compound 22 (FIG. 4) substantially inhibited the Cl -/HCO 3 -exchange 20 . Celecoxib shows substantial antitumour activity, possibly owing to its cyclooxygenase 2-, CA9-and CA12-inhibiting properties, although other mechanisms of action may also be involved 77, 78 . Compounds that specifically inhibit anion exchangers and do not interfere with other enzymes or transport proteins are not yet available.
Inhibiting other HCO 3
-exchangers. The NBC family of co-transporters is composed of: electrogenic Na + / HCO 3 -co-transporter 1 (NBC1; also known as SLC4A4), electrogenic NBC4 (also known as SLC4A5), electroneutral NBC3 (also known as SLC4A7), NDCBE and the Na + -driven Cl -/HCO 3 -exchanger NCBE (also known as SLC4A10). NBCs have a widespread tissue distribution 72 . These co-transporters facilitate the transport of Na + and HCO 3 -across the plasma membrane with an electroneutral or electrogenic (two or three HCO 3 -per Na + ) mechanism 72 . NBC3 is an electroneutral co-transporter that is involved in the regulation of pH i in the heart, skeletal muscle and kidney. Like other HCO 3 -transporters, a region in the C terminus of NBC3 (D1135-D1136) binds to CA2, and this interaction was shown to be essential for maximal HCO 3 -transport 72 . NBC1 is an electrogenic co-transporter, which operates with either a 3:1 or 2:1 HCO 3 -:Na + stoichiometry. NBC1 mediates HCO 3 -efflux from the cell to the blood, and normally works with a stoichiometry of three HCO 3 -per Na + . CA4 and NBC1 have been shown to colocalize in the mammalian kidney, pancreas and heart 19 . DIDS is an inhibitor of these transporters, but owing to its toxicity it cannot be used as a therapeutic agent 79 . Another inhibitor of these HCO 3 -transporters -S3705 -has been reported and evaluated for the inhibition of proliferation and apoptosis of the human cholangiocarcinoma cell lines HUH-28 and Mz-ChA-1 80 ; the structure of S3705, however, has not been disclosed. The pH i of the treated cells was shown to decrease following inhibition with S3705. Incubation of HUH-28 cells with cariporide (compound 24; FIG. 4) and/or S3705 reduced cell proliferation and induced apoptosis 80 . The same two agents (cariporide and S3705) were investigated for their effects on the toxicity of the anticancer drug melphalan in two human breast cancer cell lines (MDA-MB231 and MCF7) 81 , but the effects of the two drugs on pH e were too small to warrant clinical studies. Like anion exchangers, there is a lack of selective ligands for these other HCO 3 -exchangers.
Inhibitors of Na
+ /H + exchanger 1 NHE1 is expressed in cells all over the body and is one of the crucial proteins involved in pH regulation 5, 6 . NHE1 is involved in tumorigenesis, as deletion of this protein drastically reduces tumour growth 82 . The same effects have been observed using pharmacological inhibitors 6, 83 such as amiloride or cariporide 84 (compound 23 and 24; FIG. 4) . There are numerous NHE1 inhibitors that are structurally related to amiloride and cariporide, all of them possessing the pyrazine-acylguanidine scaffold that is present in amiloride along with various other substituents to the pyrazine ring 84 . The inhibition of NHE1 is useful not only for the management of tumours but also for the treatment of acute renal failure. Cardioprotective and cerebroprotective effects of NHE1 have also been reported 84 . However, owing to the diffuse presence of NHE1 in many tissues and its fundamental role in crucial physiological processes, there is a potential risk of life-threatening side effects associated with this class of agents. In fact, Sanofi has stopped the clinical development of cariporide owing to the unexpected incidence of stroke in a large Phase III clinical trial 85 . To exploit the benefits of NHE1 inhibition in the treatment of cancer, it would be crucial to develop agents that selectively target NHE1 in tumours and do not target the enzyme in healthy tissues.
Monocarboxylate transporter inhibitors
There are at least nine different isoforms of proteins that are involved in the transport of monocarboxylates into and out of cells, but MCT1, MCT2, MCT3 and MCT4 seem to have crucial physiological roles 21 . Tumour cells metabolize glucose and glutamine to meet the high bioenergetic and biosynthetic demands of continuous proliferation 86 . As mentioned above, hypoxia and oncogenic mutations favour glycolysis and promote the conversion of pyruvate to lactate, which results in the production of high amounts of lactic acid 86 . The preferential use of lactate for oxidative metabolism involves the uptake of lactate by bystander, non-hypoxic tumour cells, thus sparing glucose for hypoxic tumour cells, which cannot carry out oxidative metabolism 5, 6, 86 . MCTs (mainly MCT1) regulate the entry and exit of lactate from tumour cells 86 , and their inhibition favours the switch from lactatefuelled respiration to glycolysis, which consecutively kills hypoxic tumour cells via glucose starvation 6 . Indeed, MCTs are overexpressed in many tumours, with MCT4 also being induced by hypoxia through HIF1 signalling, although this remains a controversial issue 87 . MCT inhibitors might therefore have utility as alternative antitumour agents, and various classes of such inhibitors -including DIDS, compound 25 and 26, (FIG. 4) -are under investigation 22 . The efficacy of these inhibitors on the different MCTs varies, as well as their mechanisms of action 22 .
In a proof-of-concept study, the inhibition of MCT1 with compound 25 induced a switch from lactatefuelled respiration to glycolysis, which was accompanied by a retardation of tumour growth in a mouse model of lung carcinoma as well as in xenotransplanted human colorectal carcinoma cells 6 . This study validated MCT1 as an antitumour target 6 . In another study the expression of MCT4 in RAS-transformed fibroblasts substantially increased the gradient between pH i and pH e from 0.14 to 0.43, when compared to CCL39 wild-type tumours that do not express MCT4 (REF. 88 ). The increased pH gradients were paralleled by increased tumour growth and diminished necrotic regions, thus proving the important role of proton-lactate co-transport in tumorigenesis 88 . Although the involvement of MCTs in tumours is well established, the lack of potent, non-toxic, isoform-selective MCT inhibitors has prevented further investigation of their potential antitumour properties. Such agents are urgently needed. As mentioned above, two PTK inhibitors in clinical use -imatinib and nilotinib -also target CA2 and CA9. Three monoclonal antibodies -girentuximab, its radiolabelled variant 124 I-girentuximab and a CA9-specific auristatin antibody (BAY79-4620) -are in Phase I-III trials for kidney cancer, other solid tumours or as imaging agents. Two small-molecule CA9 inhibitors, the sulphonamide U-104 and the glycosyl coumarin GC-205, are in advanced preclinical evaluation both for imaging and for the treatment of solid tumours and metastases in which CA9 is overexpressed 47 . Several antibodies or antibody-cytokine conjugates targeting splice isoforms of tenascin C are also in Phase II-III clinical development
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. Such agents might be useful for the management of various cancers, such as brain, breast and lung cancer, as well as Hodgkin's lymphomas. Several antibody-cytokine fusion products targeting splice isoforms of fibronectin are in Phase I-II clinical development for the treatment of melanoma, brain metastases or arthritis
As outlined in this Review, the regulation of pH in tumours involves the interplay of many proteins, including: carbonic anhydrases (specifically, CA9 and CA12), anion exchangers (AE1, AE2 and AE3), NBCs, NDCBE, MCTs, NHE1 and V-ATPase. Some of these proteins are overexpressed in tumours but their particular contribution to cancer cell proliferation is poorly understood. The concerted action of these proteins ensures a slightly alkaline pH i and an acidic pH e within the tumours, which favours the proliferation of the primary tumour and the formation of metastases. The inhibition of one or more of these pH regulators causes both the pH i and the pH e values to return to normal, with the consequent impairment of tumour growth. This constitutes an antitumour mechanism that is not exploited by the classical anticancer drugs. Among these new possible antitumour targets, the inhibition of CA9 and CA12 with monoclonal antibodies or with sulphonamide-or coumarinbased small-molecule inhibitors has been proven to reverse the effects of tumour acidification, leading to the inhibition of cancer cell growth in both primary tumours and metastases. This approach may be useful for both imaging and treating tumours that overexpress these two enzymes.
There are few specific, non-toxic and effective compounds that interfere with the other pH-regulating proteins discussed in this article, but antibodies may also be useful for this purpose. Indeed, a polyclonal antibody that targets NBC3, an isoform that is mainly present in heart, has been reported to inhibit the cardiac electrogenic Na + / HCO 3 -co-transporter 89 . Similarly, antibodies that target the cardiac isoforms of other NBCs and AE3 (REFS 90, 91) have been investigated. However, studies to examine their potential role in blocking tumour acidification have not yet been performed. Nevertheless, monoclonal antibodies may circumvent some of the toxicity and selectivity issues encountered with the small-molecule compounds.
Some sulphonamides also seem to inhibit anion exchangers, whereas PPIs of the omeprazole type show antitumour effects -possibly by inhibiting V-ATPase. Potent, specific and non-toxic compounds that inhibit one or more of these proteins may represent valuable new antitumour drugs. Several antibodies, antibodycytokine conjugates and small molecules are currently in various stages of clinical development, suggesting that agents that interfere with pH regulation in tumours might soon be available in the armamentarium of antitumour drugs. Combination therapies comprising such agents and other anticancer drugs may lead to even better antitumour responses, but this hypothesis warrants further studies.
